Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin Addition During Metformin Up-titration in T2DM
NCT02791490Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin with Placebo (2 arms). Primary endpoints: Change From Baseline in Hemoglobin A1C at Week 20, Percentage of Participants Who Experienced at Least One Adverse Event at 22 weeks and 1 more. Started Jun 2016; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02791490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02791490.